Serious graft-versus-host disease after hematopoietic cell transplantation following nonmyeloablative conditioning

[1]  C. Férec,et al.  [Graft vs host disease]. , 2006, Pathologie-biologie.

[2]  M. Flowers,et al.  Chronic graft-versus-host disease. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[3]  R. Storb,et al.  Nonmyeloablative Hematopoietic Cell Transplantation: Status Quo and Future Perspectives , 2002, Journal of Clinical Immunology.

[4]  M. Maris,et al.  Relapse or progression after hematopoietic cell transplantation using nonmyeloablative conditioning: effect of interventions on outcome. , 2003, Experimental hematology.

[5]  S. Heimfeld,et al.  HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. , 2003, Blood.

[6]  J. Lynch,et al.  Performance of a new clinical grading system for chronic graft-versus-host disease: a multicenter study. , 2003, Blood.

[7]  M. Maris,et al.  Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. , 2003, Blood.

[8]  M. Maris,et al.  Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. , 2003, Blood.

[9]  M. Flowers,et al.  Evaluation of Thalidomide for Treatment or Prevention of Chronic Graft-versus-host Disease , 2003, Leukemia & lymphoma.

[10]  R. Storb,et al.  Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissio , 2003, Blood.

[11]  P. Ljungman,et al.  Risk factors for moderate-to-severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[12]  G. Gorgun,et al.  Immunologic mechanisms of extracorporeal photochemotherapy in chronic graft-versus-host disease. , 2002, Blood.

[13]  R. Storb,et al.  Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. , 2002, Blood.

[14]  H. Deeg,et al.  Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. , 2002, Blood.

[15]  H. Deeg,et al.  SIROLIMUS (RAPAMYCIN) FOR THE TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE1 , 2001, Transplantation.

[16]  J. Radich,et al.  Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. , 2001, Blood.

[17]  P. Thall,et al.  Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. , 2001, Blood.

[18]  R. Storb,et al.  Changing from cyclosporine to tacrolimus as salvage therapy for chronic graft-versus-host disease. , 2000, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[19]  Marrow Transplantation.  Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients , 2000, Biology of Blood and Marrow Transplantation.

[20]  M. Boeckh,et al.  Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. , 2000, Blood.

[21]  R. Storb,et al.  Granulocyte colony-stimulating factor given to donors before apheresis does not prevent aplasia in patients treated with donor leukocyte infusion for recurrent chronic myeloid leukemia after bone marrow transplantation. , 2000, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[22]  H. Deeg,et al.  Thalidomide for treatment of patients with chronic graft-versus-host disease. , 2000, Blood.

[23]  J. Koplan.  Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. , 2000, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[24]  S. Crawford,et al.  High rates of Pneumocystis carinii pneumonia in allogeneic blood and marrow transplant recipients receiving dapsone prophylaxis. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  N. Young,et al.  Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. , 1999, Blood.

[26]  G. Vogelsang,et al.  Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus , 1999, Bone Marrow Transplantation.

[27]  H. Hönigsmann,et al.  Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease. , 1998, Blood.

[28]  W. Hughes.  Use of dapsone in the prevention and treatment of Pneumocystis carinii pneumonia: a review. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  J Wagner,et al.  The development of chronic graft-versus-host disease: an analysis of screening studies and the impact of corticosteroid use at 100 days after transplantation , 1998, Bone Marrow Transplantation.

[30]  A. Fauser,et al.  Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients , 1998, Bone Marrow Transplantation.

[31]  A. Nagler,et al.  Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. , 1998, Blood.

[32]  A D Auerbach,et al.  Phenotypic consequences of mutations in the Fanconi anemia FAC gene: an International Fanconi Anemia Registry study. , 1997, Blood.

[33]  E. Estey,et al.  Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. , 1997, Blood.

[34]  M. Boeckh,et al.  Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. , 1996, Blood.

[35]  E. Farmer,et al.  Treatment of chronic graft-versus-host disease with ultraviolet irradiation and psoralen (PUVA). , 1996, Bone marrow transplantation.

[36]  M. Levenstein,et al.  Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study. , 1995, The Journal of infectious diseases.

[37]  E D Thomas,et al.  1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.

[38]  H. Deeg,et al.  Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. , 1992, Blood.

[39]  K. Sullivan,et al.  Chronic graft-versus-host disease and other late complications of bone marrow transplantation. , 1991, Seminars in hematology.

[40]  J. Kersey,et al.  RISK FACTORS FOR ACUTE GRAFT‐VERSUS‐HOST DISEASE IN HISTOCOMPATIBLE DONOR BONE MARROW TRANSPLANTATION , 1991, Transplantation.

[41]  D. Weisdorf,et al.  Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. , 1990, Blood.

[42]  S. Piantadosi,et al.  Predictors of death from chronic graft-versus-host disease after bone marrow transplantation. , 1989, Blood.

[43]  Jean E. Sanders,et al.  Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. , 1988, Blood.

[44]  H. Deeg,et al.  Prednisone and Azathioprine Compared With Prednisone and Placebo for Treatment of Chronic Graft-v-Host Disease : Prognostic Influence of Prolonged Thrombocytopenia After Allogeneic Marrow Transplantation , 2005 .

[45]  H. Deeg,et al.  Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings. , 1983, Annals of internal medicine.

[46]  B. M. Brown,et al.  Practical Non-Parametric Statistics. , 1981 .

[47]  K. Sullivan,et al.  Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. , 1980, The American journal of medicine.

[48]  E Niskanen,et al.  MARROW TRANSPLANTATION , 1977, Duodecim; laaketieteellinen aikakauskirja.

[49]  P. Neiman,et al.  CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S , 1974, Transplantation.